Abstract 188P
Background
Survival and prognosis data in cholangiocarcinoma patients in routine clinical practice has been limited. This study aimed to determine the survival of cholangiocarcinoma patients and to investigate prognostic factors for survival in cholangiocarcinoma patients.
Methods
This cohort study retrospectively reviewed 158 records of cholangiocarcinoma patients treated in Oncology Unit, Department of Medicine, Rajavithi hospital from 1 January 2004 to 31 December 2017. Clinical characteristics, treatments, and outcomes were collected and analyzed.
Results
There were 158 patients whose median age was 58 years old while 69.6% of those had a good performance status (ECOG PS) of 0-1. The median survival time for all was 9.5 months (95% CI = 7.3-11.6) and the 1-year survival rate was 37.3%. After curative surgery (n = 49), 35 patients (71.4%) had tumor recurrence with the median disease-free survival of 8.81 months (95% CI = 6.93-10.68). Patients who received first-line palliative chemotherapy (n = 68) had the median progression-free survival of 4.3 months (95% CI = 3.51-5.10). The overall response rate to first-line chemotherapy was 7.3%. Variables analyzed by univariate analysis including ECOG PS of 3-4 (p < 0.001), neutrophil/lymphocyte ratio >/= 4 (p 0.004), intrahepatic cholangiocarcinoma (compared with hilar cholangiocarcinoma, p 0.005), distant metastasis in all sites (p < 0.001) and TNM stage IV disease (p < 0.001) were significant factors for shorter survival time. While surgical treatment, adjuvant chemotherapy and radiation, and palliative chemotherapy were significantly associated with better survival (p < 0.001). Multivariate analysis identified ECOG PS of 3-4 (p 0.001), intrahepatic type (p 0.001) and TNM stage IV disease (p 0.033) as independent poor prognostic factors for survival. Furthermore, receiving surgery and palliative chemotherapy administration (p < 0.001) were independent significant predictors associated with better survival compared to best supportive care alone.
Conclusions
Poor ECOG performance status of 3, intrahepatic cholangiocarcinoma type and TNM stage IV disease were adverse prognostic factors whereas surgical treatment and palliative chemotherapy had a crucial role in treatment for cholangiocarcinoma patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Oncology unit, Internal Medicine Department, Rajavithi Hospital.
Funding
Rajavithi Hospital.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract